Rigel Pharmaceuticals, Inc. (RIGL) Reports Q3 Loss of $0.25
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $35.73 --0%
Financial Fact:
Total costs and expenses: 26.5M
Today's EPS Names:
MAYS, CRMT, REPL, More
Financial Fact:
Total costs and expenses: 26.5M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q3 EPS of ($0.25), versus $0.96 reported last year. Revenue for the quarter came in at $4.35 million, versus $72.28 thousand reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
- John Wiley & Sons, Inc. (WLYB) Tops Q4 EPS by 12c; Offers Outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
